Advanced Science, Volume 11, Issue 21, June 5, 2024.No available intervention definitively prevents or manages osteoporosis. In an ovariectomized rat model of postmenopausal osteoporosis, Pool 7 Compound 3 targets pivotal biomolecules involved in inflammation resolution, bone, and adipose homeostasis. Further, and within the gut microbiome, several anti‐inflammatory commensal species able to directly ...
Fei Wei +11 more
wiley +1 more source
, 2017 Osteoporosis is a metabolic skeletal disease characterized by an imbalance between osteoclast-mediated bone resorption and osteoblast-mediated bone formation.
Calignano, Antonio +9 more
core +5 more sources
Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism [PDF]
, 2020 Bone remodeling consists of resorption by osteoclasts followed by formation by osteoblasts, and osteoclasts are a source of bone formation-stimulating factors.
Andersen, Thomas Levin +19 more
core +1 more source
Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis [PDF]
, 2016 Introduction: Osteoporosis is a highly prevalent skeletal disorder characterized by compromised bone strength, usually related to decreased bone mass and microstructural alterations of bone tissue, predisposing a person to an increased risk of fracture ...
Alonso N +18 more
core +2 more sources
Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women [PDF]
Therapeutic Advances in Musculoskeletal Disease, 2015 Odanacatib is a cathepsin K inhibitor developed for the treatment of postmenopausal osteoporosis. It is a bone resorption inhibitor, but which preserves bone formation to some extent. It can be administered once a week, in tablets also containing vitamin D.
openaire +2 more sources
O papel do osteoclasto na fisiopatologia de doenças do aparelho locomotor e na condição de alvo terapêutico [PDF]
, 2013 O osteoclasto é uma célula especializada, cuja principal função é a reabsorção óssea. Está envolvida na patogénese da osteoporose, da Doença de Paget e das metástases ósseas, entre outras.
Judas, F, Silva, P
core
Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss. [PDF]
, 2019 INTRODUCTION: Pharmacological options to address the imbalance between bone resorption and accrual in osteoporosis include anti-resorptive and osteoanabolic agents.
Afroditi Papachristou +15 more
core +1 more source
Role of odanacatib in reducing bone loss due to endodontic disease: An overview
Journal of International Society of Preventive and Community Dentistry, 2016 Through a comprehensive literature review, this article provides an overview of the potential role of odanacatib (ODN) in reducing bone loss due to endodontic disease.A literature review was performed in PubMed Central, MEDLINE, Cochrane Library, and EBSCO databases. The articles identified included those published between 2002 and 2016.
Bahuguna, Rachana +3 more
openaire +3 more sources
Role of xanthan gum on physicochemical and rheological properties of rice bran oil emulsion [PDF]
, 2016 Xanthan gum is a high molecular weight substance with potential in improving emulsions properties. The formulation composition was selected on Tween 80 ternary phase diagram and was modified by the addition of xanthan gum at different concentrations (0.0%
Ahmad, Zalinah +2 more
core
Using agents that suppress bone remodeling to treat or prevent joint disease: Quo vadis? [PDF]
, 2016 Treatment of osteoarthritis (OA) with antiremodeling agents has had a mixed record of results. It is likely that remodeling suppression is only effective when used in the early phases of OA, before significant progression.
Burr, David B.
core